Special Issue

Current Trends and Future Challenges in Hepatocellular Carcinoma

Message from the Guest Editor

Liver cancer is the third leading cause of all the cancerrelated deaths in the world, and its incidence continues to rise. Hepatocellular carcinoma (HCC) represents ~80% of all the liver cancer cases.

Mechanistic studies and the development of different high-throughput technologies along with advancements in bioinformatic analyses have started unravelling the key molecular drivers of hepatocarcinogenesis development and progression. Collectively, these studies have not only underscored the need for further investigations to fully understand the complexities underlying HCC but also ways and means to discover new therapeutic targets and biomarkers to improve patient's outcomes and reduce the socioeconomic burden.

This Special Issue welcomes the submission of original research and review articles focusing on cellular, molecular, bioinformatic, epidemiological, and clinical aspects of the development of HCC, the prognosis, and its prevention. The main objectives are to explore the various mechanisms driving HCC development of various etiologies, discovering novel ways for their early diagnosis and revealing new avenues of treatment.

Guest Editor

Dr. Atish Mukherji

Institute of Translational Medicine and Liver Diseases (ITM), University of Strasbourg, Inserm UMR_S 1110, Strasbourg, France

Deadline for manuscript submissions

25 March 2026



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/218414

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

